Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Nutriband Inc. Warrant (NTRBW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: NTRBW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -73.27% | Avg. Invested days 51 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.2 | 52 Weeks Range 0.75 - 5.25 | Updated Date 06/10/2025 |
52 Weeks Range 0.75 - 5.25 | Updated Date 06/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -211.78% |
Management Effectiveness
Return on Assets (TTM) -36.45% | Return on Equity (TTM) -108.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 4420276 |
Shares Outstanding - | Shares Floating 4420276 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Nutriband Inc. Warrant
Company Overview
History and Background
Nutriband Inc. focuses on developing transdermal drug delivery systems and abuse-deterrent formulations. While specific founding year and detailed milestones for the warrant itself are not readily available separate from the parent company Nutriband Inc., the warrant represents a potential future equity stake in the company.
Core Business Areas
- Pharmaceutical Transdermal Delivery: Developing and commercializing transdermal patches for various pharmaceutical applications, including abuse-deterrent formulations.
- Nutritional Supplements: Development and sale of nutritional supplement products.
Leadership and Structure
Information on Nutriband Inc.'s leadership and organizational structure can be found on their investor relations page. Details of the warrant structure is provided within the filed prospectus.
Top Products and Market Share
Key Offerings
- AvertRx: Abuse-deterrent transdermal fentanyl patch. Market share data is not readily available; the market for abuse-deterrent opioids is competitive, with players like Teva Pharmaceuticals and Collegium Pharmaceutical (acquired by Assertio Holdings, ASRT). Revenue information for this product is not readily available. This product is not yet FDA approved.
- Nutriband: Line of Nutritional Supplements. The market share is small and no data is available. Competitors include global supplement companies like Nestle Health Science and Herbalife.
Market Dynamics
Industry Overview
The transdermal drug delivery market is growing, driven by patient preference for non-invasive drug administration and the potential for improved drug delivery profiles. The market also includes nutritional supplement markets which is a highly competitive marketplace with established companies.
Positioning
Nutriband Inc. aims to capture a niche in the transdermal drug delivery market, particularly with its abuse-deterrent technology. They are positioned as an emerging player with potential for growth but also high risks associated with regulatory approvals and market adoption.
Total Addressable Market (TAM)
The global transdermal drug delivery market is estimated to be in the billions of dollars annually. Nutriband Inc.'s TAM is dependent on the successful development and commercialization of its products and its ability to secure FDA approvals. No information is available on the TAM for nutritional supplements.
Upturn SWOT Analysis
Strengths
- Proprietary transdermal drug delivery technology
- Abuse-deterrent formulation expertise
- Potential for partnerships with pharmaceutical companies
Weaknesses
- Limited financial resources
- Dependence on regulatory approvals
- Limited commercialization experience
- Heavily reliant on third party manufacturing
Opportunities
- Expanding applications of transdermal drug delivery
- Partnerships with established pharmaceutical companies
- Increasing demand for abuse-deterrent opioid formulations
- Regulatory incentives for abuse-deterrent drugs
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Patent challenges
- Changing market dynamics in the opioid market
- Funding risk
Competitors and Market Share
Key Competitors
- TEVA
- ASRT
- JNJ
Competitive Landscape
Nutriband Inc. faces strong competition from established pharmaceutical companies with greater resources and existing market presence. Its success depends on demonstrating the superior efficacy and safety of its products.
Growth Trajectory and Initiatives
Historical Growth: Nutriband Inc.'s historical growth is tied to its product development pipeline and regulatory approvals. Historical growth is limited because the company does not have any significant revenue.
Future Projections: Future projections for Nutriband Inc. depend on the successful development and commercialization of its products, particularly AvertRx. Analyst estimates are not readily available and would be subject to significant uncertainty.
Recent Initiatives: Recent initiatives include focusing on securing FDA approval for AvertRx and exploring partnerships for commercialization.
Summary
Nutriband Inc. is a development-stage pharmaceutical company focused on transdermal drug delivery, particularly abuse-deterrent opioid formulations. The company's potential hinges on regulatory approval and successful commercialization of AvertRx. Securing partnerships with established pharmaceutical companies is vital to their growth trajectory. The company should focus on managing its cashflow to keep up with the R&D costs.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q), Nutriband Inc. Investor Relations, Industry Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is based on estimates and may not be precise. The value of Nutriband Inc. Warrant depends on the underlying stock and is subject to market volatility and the company's performance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nutriband Inc. Warrant
Exchange NASDAQ | Headquaters Orlando, FL, United States | ||
IPO Launch date 2021-10-01 | Founder, CEO & Director Mr. Gareth Sheridan | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.nutriband.com |
Full time employees - | Website https://www.nutriband.com | ||
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.